The Preclinical / Translational Studies Grant from the Osteosarcoma Institute supports translational researchers working on osteosarcoma. The proposed study should have a research agenda that will identify biological dependencies in the disease that can be targeted in patients. This research agenda will ideally include the use of novel laboratory approaches and bioinformatic tools applied to osteosarcoma cells, a diversity of in vivo models across species and human patient samples. Furthermore, we believe these dependencies will likely impact a variety of potential phenotypes associated with the disease, including metastatic proclivity, DDR in the context of a structurally complex genome, and resistance to first generation T cell checkpoint blockade. Applications are open to researchers based at non-profit organizations worldwide. Applicants must have an MD, PhD, MD/PhD, or equivalent and be appointed as faculty (or equivalent) at an academic institution. Applicants may apply for up to 500,000 USD, including up to 10% indirect costs for 2 years.
Letters of intent are due on November 15, 2023. Invited full applications are due on April 12, 2024.
April 12, 2024